GALLANT 4 Tesaglitazar vs. Glibenclamide

PHASE3TerminatedINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

December 31, 2006

Conditions
Type 2 Diabetes
Interventions
DRUG

Tesaglitazar

DRUG

Glibenclamide

Trial Locations (66)

Unknown

Research Site, Antwerp

Research Site, Braine-l'Alleud

Research Site, Hasselt

Research Site, Liège

Research Site, Merksem

Research Site, Sint-Gillis-Waas

Research Site, Steenokkerzeel

Research Site, Shatin, N.T.

Research Site, Balatonfüred

Research Site, Budapest

Research Site, Kaposvár

Research Site, Kecskemét

Research Site, Székesfehérvár

Research Site, Arenzano

Research Site, Chiavari (GE)

Research Site, Chieri

Research Site, Gubbio (PG)

Research Site, Milan

Research Site, Napoli

Research Site, Padua

Research Site, Perugia

Research Site, Piacenza

Research Site, Reggio Calabria

Research Site, Reggio Emilia

Research Site, Rho

Research Site, Roma

Research Site, Udine

Research Site, Kubang Kerian

Research Site, Kuala Lampur

Research Site, México

Research Site, Guadalajara

Research Site, Zapopan

Research Site, Veracruz

Research Site, Ås

Research Site, Bergen

Research Site, Kongsvinger

Research Site, Lysaker

Research Site, Oslo

Research Site, Skedsmokorset

Research Site, Sørumstand

Research Site, Trondheim

Research Site, Manila

Research Site, Pasig

Research Site, Krakow

Research Site, Lublin

Research Site, P³ock

Research Site, Toruñ

Research Site, Tychy

Research Site, Warsaw

Research Site, £ód?

Research Site, Bratislava

Research Site, Ilava

Research Site, Košice

Research Site, Kysucké Nové Mesto

Research Site, Lučenec

Research Site, Ľubochňa

Research Site, Nitra

Research Site, Prešov

Research Site, Trnava

Research Site, Cape Town

Research Site, Durban

Research Site, Houghton Gauteng

Research Site, Changhua

Research Site, Taichung

Research Site, Taipei

Research Site, Bangkok

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY